alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S CONSOLIDATED FINANCIAL STATEMENTS INCLUDED IN FORM 10-K AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                       9,318,000
<SECURITIES>                                         0
<RECEIVABLES>                                3,880,000
<ALLOWANCES>                                 (322,000)
<INVENTORY>                                  5,366,000
<CURRENT-ASSETS>                            19,019,000
<PP&E>                                       3,871,000
<DEPRECIATION>                               2,075,000
<TOTAL-ASSETS>                              21,323,000
<CURRENT-LIABILITIES>                        2,545,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  4,948,000
<COMMON>                                    19,409,000
<OTHER-SE>                                 (5,579,000)
<TOTAL-LIABILITY-AND-EQUITY>                21,323,000
<SALES>                                     20,455,000
<TOTAL-REVENUES>                            20,455,000
<CGS>                                        9,553,000
<TOTAL-COSTS>                                9,477,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           (373,000)
<INCOME-PRETAX>                              1,798,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          1,798,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,798,000
<EPS-PRIMARY>                                      .21
<EPS-DILUTED>                                      .20
        

</TABLE>
[No. 38690-5-I.

Division One.

November 17, 1997.]

#### The State of Washington, *Respondent,*v. Michael Nordstrom, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 95-1-04456-1, Ricardo S. Martinez, J., entered May 20, 1996. *Reversed*by unpublished opinion per Cox, J., concurred in by Agid and Ellington, JJ. Now published at 89 Wn. App. 737.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1420 Lipase enzyme preparation derived from Rhizopus niveus. ( a ) Lipase enzyme preparation contains lipase enzyme (CAS Reg. No. 9001-62-1), which is obtained from the culture filtrate resulting from a pure culture fermentation of a nonpathogenic and nontoxigenic strain of *Rhizopus niveus.* The enzyme preparation also contains diatomaceous earth as a carrier. The characterizing activity of the enzyme, which catalyzes the interesterification of fats and oils at the 1- and 3-positions of triglycerides, is triacylglycerol lipase (EC 3.1.1.3).
( b ) The ingredient meets the general requirements and additional requirements for enzyme preparations in the monograph on Enzyme Preparations in the “Food Chemicals Codex,” 4th ed. (1996), pp. 133 and 134, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme as defined in § 170.3(o)(9) of this chapter for the interesterification of fats and oils.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[63 FR 24419, May 4, 1998, as amended at 81 FR 5595, Feb. 3, 2016; 88 FR 17724, Mar. 24, 2023]
§ 19.10 Food and Drug Administration Conflict of Interest Review Board. ( a ) The Commissioner shall establish a permanent five-member Conflict of Interest Review Board, which shall review and make recommendations to the Commissioner on all specific or policy matters relating to conflicts of interest arising within the Food and Drug Administration that are forwarded to it by: ( 1 ) The Associate Commissioner for Management and Operations or
( 2 ) anyone who is the subject of an adverse determination by the Associate Commissioner for Management and Operations on any matter arising under the conflict of interest laws, except a determination of an apparent violation of law. The Director, Division of Ethics and Program Integrity, Office of Management and Operations, shall serve as executive secretary of the Review Board.
( b ) It shall be the responsibility of every Food and Drug Administration employee with whom any specific or policy issue relating to conflicts of interest is raised, or who otherwise wishes to have any such matter resolved, to forward the matter to the Associate Commissioner for Management and Operations for resolution, except that reporting of apparent violations of law are governed by § 19.21.
( c ) All general policy relating to conflicts of interest shall be established in guidance documents pursuant to the provisions of § 10.90(b) of this chapter and whenever feasible shall be incorporated in regulations in this subpart.
( d ) All decisions relating to specific individuals shall be placed in a public file established for this purpose by the Division of Freedom of Information, e.g., a determination that a consultant may serve on an advisory committee with specific limitations or with public disclosure of stock holdings, except that such determination shall be written in a way that does not identify the individual in the following situations: ( 1 ) A determination that an employee must dispose of prohibited financial interests or refrain from incompatible outside activities in accordance with established Department or agency regulations.
( 2 ) A determination that a proposed consultant is not eligible for employment by the agency.
( 3 ) A determination that public disclosure of any information would constitute an unwarranted invasion of personal privacy in violation of § 20.63 of this chapter.
[42 FR 15615, Mar. 22, 1977, as amended at 46 FR 8456, Jan. 27, 1981; 50 FR 52278, Dec. 23, 1985; 55 FR 1404, Jan. 16, 1990; 65 FR 56479, Sept. 19, 2000; 76 FR 31469, June 1, 2011]
§ 1301.16 Amendments to and withdrawal of applications. ( a ) An application may be amended or withdrawn without permission of the Administrator at any time before the date on which the applicant receives an order to show cause pursuant to § 1301.37. An application may be amended or withdrawn with permission of the Administrator at any time where good cause is shown by the applicant or where the amendment or withdrawal is in the public interest.
( b ) After an application has been accepted for filing, the request by the applicant that it be returned or the failure of the applicant to respond to official correspondence regarding the application, when sent by registered or certified mail, return receipt requested, shall be deemed to be a withdrawal of the application.
[62 FR 13949, Mar. 24, 1997]
#### § 211.196 Distribution records.

###### Cross Reference

Link to an amendment published at 89 FR 51770, June 18, 2024.

Distribution records shall contain the name and strength of the product and description of the dosage form, name and address of the consignee, date and quantity shipped, and lot or control number of the drug product. For compressed medical gas products, distribution records are not required to contain lot or control numbers.

(Approved by the Office of Management and Budget under control number 0910-0139)

[49 FR 9865, Mar. 16, 1984]
Exhibit 32 (a)
 CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
  (1)
    
    The Form 10-Q fully complies with the requirements of Section 13 (a) or
(15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78(d)); and(2)
    
    The information contained in the Form 10-Q fairly presents in all
material respects, the financial condition and results of operations of the
Partnership.
 Date:
5-14-09
 /s/
    
    JOHN S. WHETZELLJohn S. WhetzellChief Executive Officer
 A signed original of this written statement required by Section 906 has been provided to Northland
Cable Properties Seven Limited Partnership and will be retained by Northland Cable Properties Seven
Limited Partnership and furnished to the Securities and Exchange Commission or its staff upon
request.
###### Editorial Note on Part 175

#### Editorial Note:

Nomenclature changes to part 175 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; and 70 FR 72074, Dec. 1, 2005.

#### § 175.210 Acrylate ester copolymer coating.

Acrylate ester copolymer coating may safely be used as a food-contact surface of articles intended for packaging and holding food, including heating of prepared food, subject to the provisions of this section:

(a) The acrylate ester copolymer is a fully polymerized copolymer of ethyl acrylate, methyl methacrylate, and methacrylic acid applied in emulsion form to molded virgin fiber and heat-cured to an insoluble resin.

(b) Optional substances used in the preparation of the polymer and in the preparation and application of the emulsion may include substances named in this paragraph, in an amount not to exceed that required to accomplish the desired technical effect and subject to any limitation prescribed: *Provided, however,* That any substance named in this paragraph and covered by a specific regulation in subchapter B of this chapter must meet any specifications in such regulation.

| List of substances | Limitations |
| --- | --- |
| Aluminum stearate | |
| Ammonium lauryl sulfate | |
| Borax | Not to exceed the amount required as a preservative in emulsion defoamer. |
| Disodium hydrogen phosphate | Do. |
| Formaldehyde | |
| Glyceryl monostearate | |
| Methyl cellulose | |
| Mineral oil | |
| Paraffin wax | |
| Potassium hydroxide | |
| Potassium persulfate | |
| Tallow | |
| Tetrasodium pyrophosphate | |
| Titanium dioxide | |

(c) The coating in the form in which it contacts food meets the following tests:

(1) An appropriate sample when exposed to distilled water at 212 °F for 30 minutes shall yield total chloroform-soluble extractables not to exceed 0.5 milligram per square inch.

(2) An appropriate sample when exposed to *n-*heptane at 120 °F for 30 minutes shall yield total chloroform-soluble extractables not to exceed 0.5 milligram per square inch.
# L_2019156EN.01000501.xml

| 13.6.2019 | EN | Official Journal of the European Union | L 156/5 |
| --- | --- | --- | --- |

13.6.2019

EN

Official Journal of the European Union

L 156/5

---

COUNCIL DECISION (EU, Euratom) 2019/965

of 6 June 2019

appointing a member, proposed by the Portuguese Republic, of the European Economic and Social Committee

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 302 thereof,

Having regard to the Treaty establishing the European Atomic Energy Community, and in particular Article 106a thereof,

Having regard to the proposal of the Portuguese Government,

Having regard to the opinion of the European Commission,

Whereas:

| (1) | On 18 September 2015 and 1 October 2015, the Council adopted Decisions (EU, Euratom) 2015/1600 (1) and (EU, Euratom) 2015/1790 (2) appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020. |
| --- | --- |

(1)

On 18 September 2015 and 1 October 2015, the Council adopted Decisions (EU, Euratom) 2015/1600 (1) and (EU, Euratom) 2015/1790 (2) appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020.

| (2) | A member's seat on the European Economic and Social Committee has become vacant following the end of the term of office of Mr Mário David FERREIRINHA SOARES, |
| --- | --- |

(2)

A member's seat on the European Economic and Social Committee has become vacant following the end of the term of office of Mr Mário David FERREIRINHA SOARES,

HAS ADOPTED THIS DECISION:

Article 1

Mr Fernando Manuel MAURÍCIO DE CARVALHO, Member of the General Confederation of Portuguese Workers (CGTP-IN), is hereby appointed as a member of the European Economic and Social Committee for the remainder of the current term of office, which runs until 20 September 2020.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Luxembourg, 6 June 2019.

For the Council

The President

A. BIRCHALL

---

(1)  Council Decision (EU, Euratom) 2015/1600 of 18 September 2015 appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020 (OJ L 248, 24.9.2015, p. 53).

1

(2)  Council Decision (EU, Euratom) 2015/1790 of 1 October 2015 appointing the members of the European Economic and Social Committee for the period from 21 September 2015 to 20 September 2020 (OJ L 260, 7.10.2015, p. 23).

2

---
Fourth Court of Appeals

San Antonio, Texas

Friday, July 26, 2013

No. 04-12-00789-CV

Clark and Nancy Sadler,

Appellant

v.

Texas Farm Bureau Mutual Insurance Companies,

Appellee

Trial Court Case No. 11-03-00113-CVF

O R D E R

The Court has reviewed the record and briefs in this appeal and the majority of the judges

have determined that oral argument will not significantly aid it in determining the legal and

factual issues presented in the appeal. See TEX. R. APP. P. 39.8. Therefore, all requests for oral

argument are denied, and the cause is advanced for ON BRIEFS submission on Wednesday,

September 04, 2013, to the following panel: Justice Angelini, Justice Barnard, and Justice

Martinez. All parties will be notified of the Court’s decision in this appeal in accordance with

TEX. R. APP. P. 48.

Either party may file a motion requesting the Court to reconsider its determination that

oral argument will not significantly aid the Court in determining the legal and factual issues

presented in the appeal. See TEX. R. APP. P. 39.8. Such a motion should be filed within ten (10)

days from the date of this order.

It is so ORDERED on Friday, July 26, 2013.

______________________________

Karen Angelini, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said

court on this Friday, July 26, 2013.

______________________________

Keith E. Hottle, Clerk

FILE COPY
§ 21.44 Verification of identity. ( a ) An individual seeking access to records in a Privacy Act Record System may be required to comply with reasonable requirements to enable the Food and Drug Administration to determine his identity. The identification required shall be suitable considering the nature of the records sought. No identification shall be required to receive access to information that is required to be disclosed to any member of the public under part 20 of this chapter (the public information regulations).
( b ) An individual who appears in person for access to records about himself shall be required to provide at least one document to identify himself, e.g., driver's license, passport, or alien or voter registration card to verify his identity. If an individual does not have any such document or requests access to records about himself without appearing in person under circumstances in which his identity cannot be verified from the request itself, he shall be required to certify in writing that he is the individual he claims to be and that he understands that the knowing and willful request for or acquisition of a record pertaining to an individual under false pretenses is a criminal offense subject to a $5,000 fine.
( c ) In making requests under § 21.75, a parent of a minor child or legal guardian of an incompetent individual may be required to verify his relationship to the minor child or the incompetent individual, in addition to verifying his own identity, by providing a copy of the minor's birth certificate, a court order, or other evidence of guardianship.
( d ) Where an individual seeks access to particularly sensitive records, such as medical records, the individual may be required to provide additional information beyond that specified in paragraph (b) or (c) of this section, such as the individual's years of attendance at a particular educational institution, rank attained in the uniformed services, date or place of birth, names of parents, an occupation, or the specific times the individual received medical treatment.
§ 26.9 Equivalence determination. ( a ) Equivalence is established by having in place regulatory systems covering the criteria referred to in appendix D of this subpart, and a demonstrated pattern of consistent performance in accordance with these criteria. A list of authorities determined as equivalent shall be agreed to by the Joint Sectoral Committee at the end of the transition period, with reference to any limitation in terms of inspection type (e.g., postapproval or preapproval) or product classes or processes.
( b ) The parties will document insufficient evidence of equivalence, lack of opportunity to assess equivalence or a determination of nonequivalence, in sufficient detail to allow the authority being assessed to know how to attain equivalence.
### TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-03-00523-CV

Texas Workforce Commission; Diane D. Rath, in her capacity as Chairman of the Texas Workforce Commission; Commissioner Terrence P. O’Mahoney; Commissioner Ron

Lehman; Executive Director Cassie Carlson Reed, Appellants

v. Center for Public Policy Priorities, Appellee

FROM THE DISTRICT COURT OF TRAVIS COUNTY, 345TH JUDICIAL DISTRICT NO. GN303148, HONORABLE DARLENE BYRNE, JUDGE PRESIDING

M E M O R A N D U M O P I N I O N

Appellants filed a motion to dismiss this appeal because the parties have entered into

an “Agreed Final Order Granting Dismissal” of their claims in the trial co urt, thus mooting this appeal. Accordingly, we grant the motion and dismiss the appeal. S ee Tex. R. App. P. 42.1(a)(1).

W. Kenneth Law, Chief Justice Before Chief Justice Law, Justices B. A. Smith and Patterson Dismissed on Appellants’ Motion Filed: January 29, 20042
#### JAMES A. MAGUIRE, PROSECUTOR, v. CIVIL SERVICE COMMISSION OF THE STATE OF NEW JERSEY AND THE COUNTY OF CAMDEN, RESPONDENTS.

Argued January 18, 1939

Decided March 2, 1939.

*183Before Justices Case, Donges and Pokter.

Por the prosecutor, *Meyer L. Sakin.*

For the respondent Civil Service Commission of the State of New Jersey, *David T. Wilentz.*

For the respondent county of Camden, *Walter S. Keown (William A. Early King,*of counsel).

The opinion of the court was delivered by

Porter, J.

The prosecutor was a guard in the Camden county jail under appointment of the sheriff. His position was classified under the Civil Service act which was effective in that county. He was suspended by the sheriff for being intoxicated while in a public place and after hearing dismissed. He appealed this action of the sheriff to the Civil Service Commission which undertook by its decision to sustain the charge, but to minimize the penalty, saying: “On the basis of the testimony offered, it is clear that the appellant should be disciplined, but it is the conclusion of the commission that the extreme penalty of dismissal does not fit the case,” and proceeded to order that he be returned to duty after a suspension, without pay, of six months.

This court denied a writ of *mandamus,*but permitted a molding of the pleadings as though the determination had been on demurrer to a return of an alternative writ, from which an appeal was taken to the Court of Errors and Appeals.

The opinion of that court, 121 *N. J. L.*150, was delivered by the chief justice and was to the effect that the Civil Service Commission had no power or authority under the statute *184to do more than either affirm or reverse the finding of a department head and may not modify it, citing *Newark*v. *Civil Service*Commission, 115 *Id.*26.

It was further held that the judgment of the Civil Service Commission not being within its power was nugatory and wholly inoperative and void.

Thus the action of this court in denying a writ of *mandamus*was sustained.

The prosecutor now seeks a writ of *certiorari*for the purpose of reviewing the said action of the Civil Service Commission.

We conclude that a writ should not issue because, as pointed out above, the Court of Errors and Appeals has found that the order sought to be reviewed was void and so has no validity or, in fact, existence, hence there is nothing for this court to review.

The rule to show cause is discharged, with costs.
§ 111.375 Under this subpart K, what records must you make and keep? ( a ) You must make and keep records required under this subpart K in accordance with subpart P of this part.
( b ) You must make and keep records of the written procedures for manufacturing operations.
#### § 207.3 Bulk drug substance.

*Bulk drug substance,* as referenced in sections 503A(b)(1)(A) and 503B(a)(2) of the Federal Food, Drug, and Cosmetic Act, previously defined in § 207.3(a)(4), means the same as “active pharmaceutical ingredient” as defined in § 207.1.

[81 FR 60212, Aug. 31, 2016, as amended at 86 FR 17061, Apr. 1, 2021]